Developer docs
API playgroundTry for free, no card

Search company profiles

PharmaEssentia

Full company profile

uuid0000lch

Namestring
PharmaEssentia
Legal namestring
PharmaEssentia Corporation
Company typeenum
Public
Founded yearint
2003
Descriptiontext

PharmaEssentia is a Taiwan-headquartered, publicly listed biopharmaceutical company (TWSE: 6446) founded in 2003 that develops and commercializes pegylated cytokine therapies for rare hematologic diseases. Its lead asset, BESREMi (ropeginterferon alfa-2b-njft), is a next-generation mono-pegylated proline interferon built on a proprietary site-specific PEGylation platform and is the only interferon therapy approved by the FDA for adults with polycythemia vera (PV). BESREMi has secured regulatory approvals in over 40 countries including the U.S., EU, Japan, Canada, and Taiwan, and was recently approved in Taiwan for essential thrombocythemia (ET) — the first new therapy for ET in nearly 30 years — with a U.S. FDA PDUFA target action date of August 30, 2026 for the ET indication.

The company is commercializing BESREMi through a hybrid model combining direct sales operations in the U.S. (PharmaEssentia USA, Burlington, MA) and Canada (FORUS Therapeutics, acquired June 2026 for US$36.5M) with regional channel partners, including AOP Health for Europe/CIS/Middle East (~12,600 patients served) and Pint-Pharma for Latin America. BESREMi is offered as both a prefilled syringe and, following FDA approval in June 2026, a prefilled pen device for self-administration, with a U.S. WAC of approximately US$10,421 per syringe. PharmaEssentia operates GMP biologics manufacturing at Central Taiwan Science Park (capacity to serve ~40,000 patients, scaling to 100,000+), is building a US$46M facility in Puerto Rico for the U.S. market, and is advancing a pipeline that includes PEG-GCSF, an anti-PD-1 antibody, TCR-T cell therapy, bispecific immunocytokines, and novel immune checkpoint antibodies. As of Q3 2025, BESREMi sales reached US$127.8 million (44% YoY growth), with trailing twelve-month revenue growth of 61% and gross margins of 89%, reflecting a single-product-dominated commercial-stage business with substantial pipeline optionality.

Short descriptiontext

PharmaEssentia is a Taiwan-headquartered biopharmaceutical company that develops and commercializes BESREMi, an FDA-approved pegylated interferon therapy for polycythemia vera and other myeloproliferative neoplasms, distributed globally across 40+ countries to hematologists and oncology specialists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pegylated interferon therapy, hematology biopharmaceuticals, myeloproliferative neoplasm treatments, PEGylation technology platform, specialty oncology biologics
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Hematology Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales (BESREMi)
TypeOne Time License
Description

Revenue generated from global sales of BESREMi (ropeginterferon alfa-2b-njft) for polycythemia vera. Product is approved and commercially available in multiple markets including U.S., EU, Japan, and Canada. Q3 sales reached $127.8 million, up 44% year-over-year with 61% revenue growth and 89% gross margins over the trailing twelve months.

laingbuissonnews.com
2Manufacturing Services
TypeHardware Sales
Description

Expansion of manufacturing capacity through dual-site strategy (Taiwan and Puerto Rico) to support global demand for BESREMi and future pipeline products.

businesswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1BESREMi 500 mcg/ml single syringe
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Wholesale Acquisition Cost (WAC): $10,421 USD per syringe (500 mcg/ml, NDC 73536-500-01). Price as of May 15, 2026 per Colorado state pricing notification. Actual prices paid by customers may differ due to discounts, rebates, or other price reductions.

us.pharmaessentia.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1BESREMi
Description

FDA-approved product (ropeginterferon alfa-2b-njft) for treatment of adults with polycythemia vera

us.pharmaessentia.com
+8 more records
Core offering1 text field

PharmaEssentia is a Taiwan-based biopharmaceutical company that develops and commercializes BESREMi (ropeginterferon alfa-2b-njft), a proprietary mono-pegylated proline interferon therapy for adults with polycythemia vera and other myeloproliferative neoplasms. The company also manufactures biologic drug substance and drug product at GMP facilities in Taiwan and is building a second manufacturing site in Puerto Rico to support global supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 61% of patients achieved complete hematological response after 7.5 years of treatment
+5 more records
Product overview1 text field

PharmaEssentia is a biopharmaceutical company with a focused portfolio anchored by BESREMi® (ropeginterferon alfa-2b-njft), an FDA-approved mono-pegylated proline interferon therapy for polycythemia vera (PV), now also available as a convenient prefilled pen device. The company is pursuing label expansions for BESREMi® in Essential Thrombocythemia (ET) and other MPNs, supported by a growing pipeline that includes PEGylated cytokines, checkpoint antibodies, TCR-T cell therapy, and bispecific immunocytokines leveraging a proprietary site-specific PEGylation technology platform. PharmaEssentia operates GMP biologics manufacturing facilities in Taiwan and is expanding into the U.S. (Puerto Rico) to support global demand.

Product and service3 records
1BESREMi (ropeginterferon alfa-2b-njft)
CategorySpecialty Pharmaceutical — Hematology/Oncology
Description

An FDA-approved, mono-pegylated proline interferon alfa-2b therapy indicated for the treatment of adults with polycythemia vera (PV). It delivers durable hematologic and molecular responses with a favorable safety profile and every-two-weeks dosing. Prescribed by hematologists and oncology specialists.

2BESREMi Pen (ropeginterferon alfa-2b-njft prefilled pen)
CategorySpecialty Pharmaceutical — Drug Delivery Device
Description

FDA-approved prefilled pen device for self-administration of ropeginterferon alfa-2b-njft by adult patients with polycythemia vera. Designed to simplify administration and improve patient adherence compared to pre-filled syringe presentation.

3PharmaEssentia SOURCE Patient Support Program
CategoryPatient Support Services
Description

A patient services program providing personalized support to patients prescribed BESREMi to facilitate onboarding, access, adherence, and ongoing treatment continuation.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-22
Description

Taiwan government office organized 33-company delegation to BIO International Convention 2026. Supports cross-border investment, technology licensing, and joint co-development initiatives for Taiwan biotech companies.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

PharmaEssentia acquired 100% of FORUS Therapeutics for US$36.5 million to integrate Canadian regulatory, medical affairs, marketing, and commercial channel resources. FORUS had previously submitted New Drug Submission to Health Canada for BESREMi in July 2025 and received approval in July 2026. The FORUS team brings more than 25 years of hematology and oncology commercialization experience with backgrounds at Celgene, Roche, Pfizer.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

Jointly created PharmaEssentia Innovation Award to support biotech startups in Taiwan and Japan. First prize of $100,000 with total prize pool of $200,000. Focus on blood disorders, cancer, rare diseases, autoimmune diseases, AI/ML drug discovery, and cell therapy platforms.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

FORUS Therapeutics partnership opportunity for Karyopharm's XPOVIO product in Canadian market as part of PharmaEssentia's acquisition of FORUS.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-10-03
Description

Entered into exclusive global license agreement with WuXi Biologics for a myeloid immune checkpoint antibody candidate. Expands PharmaEssentia's pipeline into novel immune checkpoint targets.

6Pint-Pharma
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-02
Description

Selected as commercial partner for BESREMi (ropeginterferon alfa-2b-njft) in Latin America regions to expand market access.

us.pharmaessentia.com
7AOP Health (AOP Orphan Pharmaceuticals GmbH)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2009-01-01
Description

AOP Health acquired development and commercialization rights for BESREMi in European, CIS, and Middle Eastern markets from PharmaEssentia in 2009. Has made BESREMi available to approximately 12,600 patients in licensed territory. Frankfurt court upheld arbitral award in favor of AOP Health in April 2026.

businesswire.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Broad oncology/hematology incumbent where Eric Vogel (now PharmaEssentia's US Head of Commercialization) previously held senior commercial leadership roles; comparable in targeting oncology specialists and rare cancer indications.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for hematologic diseases including rare anemias and hematologic malignancies; comparable as an emerging player pursuing specialty hematology indications with differentiated biologics.

TypeBroad incumbent
Description

Major oncology/hematology incumbent with deep relationships with hematologists globally, including in MPNs and chronic myeloid disorders; represents the kind of broad competitor PharmaEssentia encounters in international markets.

TypeEmerging player
Description

Specialty oncology biotech focused on hematologic malignancies (XPOVIO/selinexor); relevant emerging peer given PharmaEssentia's FORUS acquisition included a Karyopharm partnership for the Canadian market and overlapping focus on rare blood cancers.

TypeBroad incumbent
Description

Global biopharma with extensive hematology/oncology portfolio and large specialty biologics infrastructure; operates in adjacent MPN/cancer therapeutics and competes for the same prescriber mindshare.

TypeDirect peer
Description

Direct competitor in MPNs with Jakafi (ruxolitinib) as the standard-of-care for PV and myelofibrosis; both companies target hematologists/oncologists with specialty biologics for rare blood cancers. PharmaEssentia even hired ex-Incyte GVP Eric Vogel to lead US commercialization.

7Bristol-Myers Squibb
TypeBroad incumbent
Description

Acquired Fedratinib (Inrebic) for myelofibrosis via Celgene, directly competing in MPNs. BMS is a broad hematology/oncology incumbent with the commercial scale to compete against BESREMi across indications.

8AOP Orphan Pharmaceuticals (AOP Health)
TypeDirect peer
Description

Exclusive commercial partner for BESREMi across Europe/CIS/Middle East since 2009; AOP Health is itself a rare disease specialty pharma focused on hematology/oncology including MPNs and directly comparable as a channel and as a competing MPN-focused company.

TypeDirect peer
Description

European-headquartered rare disease specialty pharma with hematology/oncology focus, comparable to PharmaEssentia in business model (orphan/specialty biologics for rare blood disorders) and international footprint.

TypeBroad incumbent
Description

Global pharma with substantial hematology/oncology portfolio including rare blood disorder therapies (e.g., Adynovate for hemophilia); broad incumbent competing for the same specialty hematology prescriber audience.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmaEssentia

Hematology Biopharmaceuticalsus.pharmaessentia.com

PharmaEssentia is a Taiwan-headquartered biopharmaceutical company that develops and commercializes BESREMi, an FDA-approved pegylated interferon therapy for polycythemia vera and other myeloproliferative neoplasms, distributed globally across 40+ countries to hematologists and oncology specialists.

What PharmaEssentia does

PharmaEssentia is a Taiwan-headquartered, publicly listed biopharmaceutical company (TWSE: 6446) founded in 2003 that develops and commercializes pegylated cytokine therapies for rare hematologic diseases. Its lead asset, BESREMi (ropeginterferon alfa-2b-njft), is a next-generation mono-pegylated proline interferon built on a proprietary site-specific PEGylation platform and is the only interferon therapy approved by the FDA for adults with polycythemia vera (PV). BESREMi has secured regulatory approvals in over 40 countries including the U.S., EU, Japan, Canada, and Taiwan, and was recently approved in Taiwan for essential thrombocythemia (ET) — the first new therapy for ET in nearly 30 years — with a U.S. FDA PDUFA target action date of August 30, 2026 for the ET indication.

The company is commercializing BESREMi through a hybrid model combining direct sales operations in the U.S. (PharmaEssentia USA, Burlington, MA) and Canada (FORUS Therapeutics, acquired June 2026 for US$36.5M) with regional channel partners, including AOP Health for Europe/CIS/Middle East (~12,600 patients served) and Pint-Pharma for Latin America. BESREMi is offered as both a prefilled syringe and, following FDA approval in June 2026, a prefilled pen device for self-administration, with a U.S. WAC of approximately US$10,421 per syringe. PharmaEssentia operates GMP biologics manufacturing at Central Taiwan Science Park (capacity to serve ~40,000 patients, scaling to 100,000+), is building a US$46M facility in Puerto Rico for the U.S. market, and is advancing a pipeline that includes PEG-GCSF, an anti-PD-1 antibody, TCR-T cell therapy, bispecific immunocytokines, and novel immune checkpoint antibodies. As of Q3 2025, BESREMi sales reached US$127.8 million (44% YoY growth), with trailing twelve-month revenue growth of 61% and gross margins of 89%, reflecting a single-product-dominated commercial-stage business with substantial pipeline optionality.

PharmaEssentia firmographics

Firmographics
Name
PharmaEssentia
Legal name
PharmaEssentia Corporation
Website
https://us.pharmaessentia.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
251–500 employees
Short description
PharmaEssentia is a Taiwan-headquartered biopharmaceutical company that develops and commercializes BESREMi, an FDA-approved pegylated interferon therapy for polycythemia vera and other myeloproliferative neoplasms, distributed globally across 40+ countries to hematologists and oncology specialists.
Ownership category
akta.pro rank

PharmaEssentia industry classification

Industry
Product category
Hematology Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Pegylated interferon therapy
  • Hematology biopharmaceuticals
  • Myeloproliferative neoplasm treatments
  • PEGylation technology platform
  • Specialty oncology biologics

Where PharmaEssentia is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices10 records

Markets served

PharmaEssentia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales (BESREMi): Revenue generated from global sales of BESREMi (ropeginterferon alfa-2b-njft) for polycythemia vera. Product is approved and commercially available in multiple markets including U.S., EU, Japan, and Canada. Q3 sales reached $127.8 million, up 44% year-over-year with 61% revenue growth and 89% gross margins over the trailing twelve months.
  2. Manufacturing Services: Expansion of manufacturing capacity through dual-site strategy (Taiwan and Puerto Rico) to support global demand for BESREMi and future pipeline products.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goBESREMi 500 mcg/ml single syringe

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

PharmaEssentia product offering

Product offering

Core offering

PharmaEssentia is a Taiwan-based biopharmaceutical company that develops and commercializes BESREMi (ropeginterferon alfa-2b-njft), a proprietary mono-pegylated proline interferon therapy for adults with polycythemia vera and other myeloproliferative neoplasms. The company also manufactures biologic drug substance and drug product at GMP facilities in Taiwan and is building a second manufacturing site in Puerto Rico to support global supply.

Product overview

PharmaEssentia is a biopharmaceutical company with a focused portfolio anchored by BESREMi® (ropeginterferon alfa-2b-njft), an FDA-approved mono-pegylated proline interferon therapy for polycythemia vera (PV), now also available as a convenient prefilled pen device. The company is pursuing label expansions for BESREMi® in Essential Thrombocythemia (ET) and other MPNs, supported by a growing pipeline that includes PEGylated cytokines, checkpoint antibodies, TCR-T cell therapy, and bispecific immunocytokines leveraging a proprietary site-specific PEGylation technology platform. PharmaEssentia operates GMP biologics manufacturing facilities in Taiwan and is expanding into the U.S. (Puerto Rico) to support global demand.

Differentiator

Problem solved

Functional benefit

Brands

  • BESREMi: FDA-approved product (ropeginterferon alfa-2b-njft) for treatment of adults with polycythemia vera
  • BESREMi Pen
  • Piece Together PV
  • Piece Together ET
  • PV in Focus
  • PharmaEssentia SOURCE
  • MPN Pod: Stories from the Marrow
  • ChangePV
  • PharmaEssentia Medical

Products and services

  • BESREMi (ropeginterferon alfa-2b-njft) An FDA-approved, mono-pegylated proline interferon alfa-2b therapy indicated for the treatment of adults with polycythemia vera (PV). It delivers durable hematologic and molecular responses with a favorable safety profile and every-two-weeks dosing. Prescribed by hematologists and oncology specialists.
  • BESREMi Pen (ropeginterferon alfa-2b-njft prefilled pen) FDA-approved prefilled pen device for self-administration of ropeginterferon alfa-2b-njft by adult patients with polycythemia vera. Designed to simplify administration and improve patient adherence compared to pre-filled syringe presentation.
  • PharmaEssentia SOURCE Patient Support Program A patient services program providing personalized support to patients prescribed BESREMi to facilitate onboarding, access, adherence, and ongoing treatment continuation.

Quantifiable outcome

  • 61% of patients achieved complete hematological response after 7.5 years of treatment
  • +5 more outcomes

Companies that use PharmaEssentia

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

PharmaEssentia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

PharmaEssentia partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor, core and secondary.

  • Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO)minorGTM or Marketing Partner · 22 June 2026Taiwan government office organized 33-company delegation to BIO International Convention 2026. Supports cross-border investment, technology licensing, and joint co-development initiatives for Taiwan biotech companies.
  • FORUS Therapeutics Inc.coreChannel Partner/ Reseller/ Distributor · 11 June 2026PharmaEssentia acquired 100% of FORUS Therapeutics for US$36.5 million to integrate Canadian regulatory, medical affairs, marketing, and commercial channel resources. FORUS had previously submitted New Drug Submission to Health Canada for BESREMi in July 2025 and received approval in July 2026. The FORUS team brings more than 25 years of hematology and oncology commercialization experience with backgrounds at Celgene, Roche, Pfizer.
  • TECH-TokyominorStrategic or Co-development Partner · 8 April 2026Jointly created PharmaEssentia Innovation Award to support biotech startups in Taiwan and Japan. First prize of $100,000 with total prize pool of $200,000. Focus on blood disorders, cancer, rare diseases, autoimmune diseases, AI/ML drug discovery, and cell therapy platforms.
  • Karyopharm TherapeuticsminorStrategic or Co-development Partner · 1 January 2024FORUS Therapeutics partnership opportunity for Karyopharm's XPOVIO product in Canadian market as part of PharmaEssentia's acquisition of FORUS.
  • WuXi BiologicscoreTechnology or Integration · 3 October 2023Entered into exclusive global license agreement with WuXi Biologics for a myeloid immune checkpoint antibody candidate. Expands PharmaEssentia's pipeline into novel immune checkpoint targets.
  • Pint-PharmasecondaryChannel Partner/ Reseller/ Distributor · 2 June 2023Selected as commercial partner for BESREMi (ropeginterferon alfa-2b-njft) in Latin America regions to expand market access.
  • AOP Health (AOP Orphan Pharmaceuticals GmbH)coreChannel Partner/ Reseller/ Distributor · 1 January 2009AOP Health acquired development and commercialization rights for BESREMi in European, CIS, and Middle Eastern markets from PharmaEssentia in 2009. Has made BESREMi available to approximately 12,600 patients in licensed territory. Frankfurt court upheld arbitral award in favor of AOP Health in April 2026.

Scale indicators12 records

Recent moves8 records

Expansion highlights8 records

PharmaEssentia competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: Broad oncology/hematology incumbent where Eric Vogel (now PharmaEssentia's US Head of Commercialization) previously held senior commercial leadership roles; comparable in targeting oncology specialists and rare cancer indications.
  • Novartis: Major oncology/hematology incumbent with deep relationships with hematologists globally, including in MPNs and chronic myeloid disorders; represents the kind of broad competitor PharmaEssentia encounters in international markets.
  • Roche: Global biopharma with extensive hematology/oncology portfolio and large specialty biologics infrastructure; operates in adjacent MPN/cancer therapeutics and competes for the same prescriber mindshare.
  • Bristol-Myers Squibb: Acquired Fedratinib (Inrebic) for myelofibrosis via Celgene, directly competing in MPNs. BMS is a broad hematology/oncology incumbent with the commercial scale to compete against BESREMi across indications.
  • Takeda Pharmaceutical: Global pharma with substantial hematology/oncology portfolio including rare blood disorder therapies (e.g., Adynovate for hemophilia); broad incumbent competing for the same specialty hematology prescriber audience.

Emerging players

  • Disc Medicine: Clinical-stage biotech developing therapeutics for hematologic diseases including rare anemias and hematologic malignancies; comparable as an emerging player pursuing specialty hematology indications with differentiated biologics.
  • Karyopharm Therapeutics: Specialty oncology biotech focused on hematologic malignancies (XPOVIO/selinexor); relevant emerging peer given PharmaEssentia's FORUS acquisition included a Karyopharm partnership for the Canadian market and overlapping focus on rare blood cancers.

Direct peers

  • Incyte Corporation: Direct competitor in MPNs with Jakafi (ruxolitinib) as the standard-of-care for PV and myelofibrosis; both companies target hematologists/oncologists with specialty biologics for rare blood cancers. PharmaEssentia even hired ex-Incyte GVP Eric Vogel to lead US commercialization.
  • AOP Orphan Pharmaceuticals (AOP Health): Exclusive commercial partner for BESREMi across Europe/CIS/Middle East since 2009; AOP Health is itself a rare disease specialty pharma focused on hematology/oncology including MPNs and directly comparable as a channel and as a competing MPN-focused company.
  • Sobi (Swedish Orphan Biovitrum): European-headquartered rare disease specialty pharma with hematology/oncology focus, comparable to PharmaEssentia in business model (orphan/specialty biologics for rare blood disorders) and international footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

PharmaEssentia social profiles

Digital presence

PharmaEssentia compliance and trust

Trust signal

Compliance7 records

PharmaEssentia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmaEssentia leadership team

Management profile

Number of profiles

Profiles13 records

PharmaEssentia subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

PharmaEssentia funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmaEssentia M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaEssentia

What does PharmaEssentia do?

PharmaEssentia is a Taiwan-based biopharmaceutical company that develops and commercializes BESREMi (ropeginterferon alfa-2b-njft), a proprietary mono-pegylated proline interferon therapy for adults with polycythemia vera and other myeloproliferative neoplasms. The company also manufactures biologic drug substance and drug product at GMP facilities in Taiwan and is building a second manufacturing site in Puerto Rico to support global supply.

Is PharmaEssentia a public or private company?

PharmaEssentia is a public company. It is classified as public and is currently operating.

When was PharmaEssentia founded?

PharmaEssentia was founded in 2003. It employs 251 to 500 people.

Where is PharmaEssentia based?

PharmaEssentia is headquartered in Burlington, United States, in the North America region.

How does PharmaEssentia make money?

Two revenue lines are on record. Pharmaceutical Product Sales (BESREMi) is the primary driver. The others are manufacturing Services.

Who are PharmaEssentia's main competitors?

Broad incumbents on record are AstraZeneca, Novartis, Roche, Bristol-Myers Squibb and Takeda Pharmaceutical. Emerging players are Disc Medicine and Karyopharm Therapeutics. Direct peers are Incyte Corporation, AOP Orphan Pharmaceuticals (AOP Health) and Sobi (Swedish Orphan Biovitrum).

Does PharmaEssentia have an API?

No public API is recorded for PharmaEssentia.

What industry is PharmaEssentia in?

PharmaEssentia's product category is Hematology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterPharmaEssentia spotlights European gap as Ropeg wins essential thrombocythemia approvals elsewherePharmaEssentia highlighted the absence of a European indication for its Ropeg in essential thrombocythemia, noting the drug is approved in Taiwan, Japan, the US, and China but not the EU. The EU approved Ropeg in 2019 for polycythemia vera, but PharmaEssentia said that approval does not extend to ET, which requires its own evidence and regulatory assessment.FinancialContent Business PagePharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid TumorsPharmaEssentia will present two poster presentations at the SITC annual meeting in Phoenix, November 4-8, showcasing preclinical data for PEC2001 and PEC3001. The myeloid checkpoint inhibitor and immunocytokine show enhanced anti-tumor activity, supporting advancement toward clinical development. The company plans to move solid tumor candidates into IND-enabling and Phase 1 studies.FinanzNachrichten.dePharmaEssentia Corporation: Von Taiwan in die Welt: PharmaEssentia baut ein von Wissenschaftlern geführtes, vollständig integriertes globales biopharmazeutisches Unternehmen auf, bei dem die PatientenPharmaEssentia Corporation, a Taiwan-based biopharmaceutical company, received US and Japan approvals for Ropeginterferon alfa-2b (BESREMi) for essential thrombocythemia, following a Taiwan approval. The drug, the first new ET therapy in nearly three decades, is also approved for polycythemia vera. The company is conducting a Phase 3 study for primary myelofibrosis and plans a $46 million Puerto Rico production facility.MorningstarPharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingPharmaEssentia will present two poster presentations at the 2026 SOHO Annual Meeting in Houston, including two-year Phase 3 SURPASS-ET data and real-world evidence for BESREMi in essential thrombocythemia. The extension showed maintained response rates and platelet control through two years, with ongoing long-term analyses.Pharmaceutical TechnologyPharmaEssentia’s Besremi receives FDA approval for ETThe FDA approved PharmaEssentia's Besremi for essential thrombocythaemia, the first ET treatment in nearly 30 years. The decision follows the Phase III SURPASS ET trial, which showed superior durable response rates and fewer thromboembolic events versus anagrelide. The approval expands Besremi's existing indication for polycythaemia vera.BioSpaceFDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood CancerThe FDA approved BESREMi (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia, the first new ET treatment in nearly three decades. The approval is based on the global Phase 3 SURPASS ET trial, which showed durable ELN responses and reduced thromboembolic events over 12 months. The drug is available in the U.S. immediately upon approval.FiercePharmaOn the 'cusp,' PharmaEssentia gains FDA label expansion for BesremiThe FDA approved a label expansion for Besremi to treat essential thrombocythemia, making it the first new product approved in the indication since 1997. The approval covers adults regardless of genotype or disease status, including newly diagnosed patients. PharmaEssentia reported $494 million in revenue last year, with Besremi potentially reaching $1 billion this year.AETOSWireICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® ProceedingsAn ICC Arbitral Tribunal awarded AOP Health about EUR 112 million in a quantum award against PharmaEssentia over BESREMi® licensing. The award quantifies damages at EUR 82 million and overpayments at EUR 31 million, confirming PharmaEssentia overcharged by up to 900%. PharmaEssentia's remaining claims were dismissed, and AOP Health owes no payment.Financial PostICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® ProceedingsAn ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals approximately EUR 112 million in damages against PharmaEssentia Corp. for intentional breaches of their licensing agreement regarding the drug BESREMi®. The award confirms that PharmaEssentia overcharged AOP Health by up to 900% between 2019 and 2022, resulting in a net liability for PharmaEssentia after set-offs. This decision follows a February 2025 ruling that established PharmaEssentia's liability, with proceedings now focused on quantifying the financial penalties.Business Wire BlogICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® ProceedingsAn ICC Arbitral Tribunal awarded AOP Orphan Pharmaceuticals GmbH approximately EUR 112 million in damages and reimbursement against PharmaEssentia Corp. for intentional breaches of their licensing agreement concerning the drug BESREMi®. The tribunal confirmed that PharmaEssentia overcharged AOP Health by up to 900% between 2019 and 2022, resulting in a net liability for PharmaEssentia with all of its remaining claims dismissed.